US EditionNeogap Receives Approval to Administer Full Dose in Cell Therapy Trial for Colorectal Cancer - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
TAK-113-4002: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
TAK-113-4002: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer Andrew Phifer Wed, 05/28/2025
Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer - Pharmafile
Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the full dose of its investigational cell therapy to all patients in its ongoing phase 1 and 2 trial for advanced colorectal cancer. The approval allows for a revised study protocol that removes the initial dose-escalation step, allowing all participants to […] The post Neogap receives approval to administer full dose in cell therapy trial…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
